Company: G
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001398659-25-000109
Chunk: 78

Company: Genpact LTD
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 78
---
 are credited or debited with notional investment gains and losses equal to the performance of selected hypothetical investment funds offered under the Plan and elected by the participant.The Company has investments in funds held in Company-owned life insurance policies which are held in a Rabbi Trust that are classified as trading securities. Management determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date.The liability for the deferred compensation plan was $60,924 and $72,663 as of December 31, 2024 and September 30, 2025, respectively, and is included in “accrued expenses and other current liabilities” and “other liabilities” in the consolidated balance sheets.  In connection with the administration of the Plan, the Company has purchased Company-owned life insurance policies insuring the lives of certain employees. The cash surrender value of these policies was $61,549 and $73,279 as of December 31, 2024 and September 30, 2025, respectively. The cash surrender value of these insurance policies is included in “other assets” in the consolidated balance sheets.

34

GENPACT LIMITED AND ITS SUBSIDIARIESNotes to the Consolidated Financial Statements(Unaudited)(In thousands, except per share data and share count)

14. Employee benefit plans (Continued)During the three months ended September 30, 2024 and 2025, the change in the fair value of Plan assets was $3,252 and $4,089, respectively, and during the nine months ended September 30, 2024 and 2025, the change in the fair value of Plan assets was $7,461 and $8,551, respectively, which is included in “other income (expense), net,” in the consolidated statements of income. During the three months ended September 30, 2024 and 2025, the change in the fair value of deferred compensation liabilities was $3,297 and $4,097, respectively, and during the nine months ended September 30, 2024 and 2025, the change in the fair value of deferred compensation liabilities was $7,453 and $8,560, respectively, which is included in “selling, general and administrative expenses.”

15. Stock-based compensation

The Company has granted stock-based awards, including options, restricted share unit awards and performance share unit awards, under the Genpact Limited 2007 Omnibus In